BCIRG-005对照组十年随访:1–3枚阳性淋巴结患者术后放疗效应
基于BCIRG-005对照组1649例淋巴结阳性乳腺癌患者的队列数据,其中523例1–3枚阳性淋巴结患者接受乳房切除,39%接受术后放疗。中位随访10年,术后放疗将局部区域控制率从91%提高至98%(p=0.001),但对总生存无影响(84% vs 86%,p=0.9)。
要点
- 1–3枚阳性淋巴结乳房切除患者中,术后放疗改善局部区域控制(91%→98%)。
- 术后放疗未显著改善总生存(84% vs 86%,p=0.9)。
- 多因素分析显示放疗降低局部复发风险(HR 0.14)和局部区域复发风险(HR 0.15)。
核心结论
- 在接受现代系统治疗的N1乳腺癌患者中,术后放疗改善局部区域控制但不影响总生存。
研究设计与样本
- 队列研究,使用BCIRG-005对照组中1649例淋巴结阳性女性的个体数据,患者于2000–2003年接受多柔比星/环磷酰胺序贯多西他赛治疗。
- 所有患者接受乳房切除或肿块切除及腋窝淋巴结清扫,术后放疗由研究者决定。
- 共523例1–3枚阳性淋巴结患者接受乳房切除,其中39%(206/523)接受术后放疗。
主要发现
- 中位随访10年,术后放疗将局部区域控制率从91%提高至98%(p=0.001)。
- 术后放疗对总生存无影响(84% vs 86%,p=0.9)。
- 多因素分析中,术后放疗改善局部控制(风险比0.14;95%CI 0.03–0.62;p=0.01)和局部区域控制(风险比0.15;95%CI 0.04–0.50;p=0.002)。
- 多因素分析中术后放疗未显著影响总生存(风险比0.91;95%CI 0.55–1.51;p=0.7)。
- 倾向性评分分析结果一致。
临床怎么用
- 对于接受现代系统治疗的1–3枚阳性淋巴结乳房切除患者,术后放疗可考虑用于改善局部区域控制。
- 应与患者讨论术后放疗对总生存无显著获益的证据。
局限性
- 术后放疗由研究者决定,非随机分配。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We evaluated the effect of post-mastectomy radiation (PMRT) in 1-3 positive lymph nodes (LN) in patients who received uniform modern systemic therapy. MATERIALS AND METHODS: Cohort study using individual data collected for 1,649 node-positive women who received doxorubicin/cyclophosphamide with sequential docetaxel in 2000-2003 on the control arm of BCIRG-005. All women underwent mastectomy or lumpectomy and axillary LN dissection. PMRT was given at investigator's discretion. RESULTS: A total of 523 women with 1-3 positive LN underwent mastectomy and 39% (206/523) received PMRT. With a median follow-up of 10years, PMRT improved loco-regional control (LRC) from 91% to 98% (p=0.001) but had no effect on overall survival (OS) (84% vs. 86%, p=0.9). On multivariate analysis, PMRT improved local control (LC) (hazard ratio, 0.14; 95% CI, 0.03-0.62; p=0.01) and LRC (hazard ratio, 0.15; 95% CI, 0.04-0.50; p=0.002). PMRT did not significantly impact OS on multivariate analysis (hazard ratio, 0.91; 95% CI, 0.55-1.51; p=0.7). Results remained consistent with the use of propensity score analysis. CONCLUSIONS: In this cohort of patients with N1 disease treated with modern systemic therapy, PMRT improves LRC but has no effect on OS. The rates of OS were excellent, irrespective of adjuvant radiation.
引用
- Tam MM, Wu SP, Perez C, et al. The effect of post-mastectomy radiation in women with one to three positive nodes enrolled on the control arm of BCIRG-005 at ten year follow-up. Radiother Oncol. 2017. PMID: 28341062. doi:10.1016/j.radonc.2017.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。